Ogasawara, Ken http://orcid.org/0000-0002-4264-8927
Dodds, Michael
Mack, Timothy
Lymp, James
Dell’Aringa, Justine
Smith, Jeff
Clinical trials referenced in this document:
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
https://doi.org/10.1136/jitc-2020-001235
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
https://doi.org/10.1007/s40262-021-01039-5
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
https://doi.org/10.1186/s40164-022-00268-z
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
https://doi.org/10.1200/jco.23.02214
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
https://doi.org/10.1136/jitc-2020-002056
Funding for this research was provided by:
Juno Therapeutics
Article History
Accepted: 11 May 2021
First Online: 14 June 2021
Change Date: 3 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40262-021-01055-5
Declarations
:
: This study was funded by Juno Therapeutics, a Bristol-Myers Squibb Company.
: Ken Ogasawara, Timothy Mack, James Lymp, Justine Dell’Aringa, and Jeff Smith are employees of Bristol Myers Squibb and hold stock in Bristol Myers Squibb. Michael Dodds is a consultant for Bristol Myers Squibb.
: The research was conducted within all the appropriate ethical and legal guidelines.
: For investigations involving human patients, informed consent was obtained from the participants involved.
: All authors approved this manuscript for submission.
: Bristol Myers Squibb policy on data sharing may be found at ExternalRef removed.
: KO and MD contributed to the study design and data analysis and interpretation. TM, JL, JD, and JS contributed to data acquisition and interpretation. KO drafted the manuscript. All authors critically reviewed the draft manuscript, approved the final version to be published, and agree to be accountable for all aspects of the work.